Century Therapeutics, Inc.
IPSC
$2.21
$0.094.25%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | 0.00 | -- | -- | 109.16M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 0.00 | -- | -- | 109.16M |
| Cost of Revenue | 17.11M | 19.70M | 22.53M | 26.86M | 26.58M |
| Gross Profit | -17.11M | -19.70M | -22.53M | -26.86M | 82.58M |
| SG&A Expenses | 8.40M | 5.88M | 6.84M | 7.81M | 8.65M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.50M | 25.57M | 29.36M | 34.66M | 35.23M |
| Operating Income | -25.50M | -25.57M | -29.36M | -34.66M | 73.94M |
| Income Before Tax | -21.65M | -19.24M | -34.42M | -32.54M | 76.56M |
| Income Tax Expenses | -- | -68.00K | -- | -- | -- |
| Earnings from Continuing Operations | -21.65M | -19.17M | -34.42M | -32.54M | 76.56M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.65M | -19.17M | -34.42M | -32.54M | 76.56M |
| EBIT | -25.50M | -25.57M | -29.36M | -34.66M | 73.94M |
| EBITDA | -22.50M | -22.02M | -26.23M | -31.46M | 77.16M |
| EPS Basic | -0.11 | -0.22 | -0.40 | -0.38 | 0.89 |
| Normalized Basic EPS | -0.08 | -0.17 | -0.20 | -0.24 | 0.55 |
| EPS Diluted | -0.11 | -0.22 | -0.40 | -0.38 | 0.89 |
| Normalized Diluted EPS | -0.08 | -0.17 | -0.20 | -0.24 | 0.55 |
| Average Basic Shares Outstanding | 193.47M | 87.29M | 86.46M | 86.24M | 86.02M |
| Average Diluted Shares Outstanding | 193.47M | 87.29M | 86.46M | 86.24M | 86.10M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |